TargetMol

Zaltoprofen

Product Code:
 
TAR-T6737
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T6737-5mg5mg£100.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6737-10mg10mg£115.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6737-1mL1 mL * 10 mM (in DMSO)£120.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6737-25mg25mg£143.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6737-50mg50mg£161.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6737-100mg100mg£193.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6737-200mg200mg£230.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Zaltoprofen is a Cox-1 and Cox-2 inhibitor, which is used for the treatment of arthritis.
CAS:
74711-43-6
Formula:
C17H14O3S
Molecular Weight:
298.36
Pathway:
Neuroscience; Immunology/Inflammation
Purity:
0.9805
SMILES:
CC(C(O)=O)c1ccc2Sc3ccccc3C(=O)Cc2c1
Target:
COX

References

Okamoto T, et al. Int J Mol Med, 2001, 8(3), 315-317. Hirate K, et al. Neurosci Res, 2006, 54(4), 288-294. Tang HB, et al. Neuropharmacology, 2005, 48(7), 1035-1042. Matsumoto M, et al. Neurosci Lett, 2006, 397(3), 249-253. Okamoto T, et al. Int J Mol Med, 2002, 9(4), 369-372.